AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30040002 — intervention group
Group type: COMPARATOR
Intervention: Threshold training
Number of subjects: 22
Study 28617838 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tesamorelin
Number of subjects: 53
Study 28617838 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study 25773683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Education (NE) program for 6 months
Number of subjects: 130
Study 23975476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (directly observed treatment)
Number of subjects: 0
Study 23975476 — intervention group
Group type: COMPARATOR
Intervention: Referral to a local public mental health clinic (control)
Number of subjects: 0
Study 21256308 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filters on both arterial and cardioplegia lines
Number of subjects: 82
Study 21256308 — intervention group
Group type: COMPARATOR
Intervention: Standard arterial filters
Number of subjects: 82
Study 18989717 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacylglycerol (DAG) supplementation
Number of subjects: 7
Study 18989717 — intervention group
Group type: COMPARATOR
Intervention: TAG oil (control)
Number of subjects: 7
Study 16815689 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin (2 g i.v. over 0.5 h as a loading dose followed by 8 g i.v. daily over 24 h)
Number of subjects: 40
Study 16815689 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin (3 g i.v. every 6h over 0.5 h)
Number of subjects: 40
Study 16815689 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin
Number of subjects: 40
Study 16815689 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin
Number of subjects: 40
Study 15049402 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg tablet once daily for 2 weeks
Number of subjects: 1862
Study 15049402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1862
Study 11819866 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiwei Baizhu Powder (QWBZP)
Number of subjects: 83
Study 11819866 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS)
Number of subjects: 83
Study 11819866 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiwei Baizhu Powder (QWBZP) in animal models
Number of subjects: 83
Study 11819866 — intervention group
Group type: COMPARATOR
Intervention: Control group (ORS in animal models)
Number of subjects: 83
Study 9491825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral forearm plethysmography (FBF ratios) at rest
Number of subjects: 9
Study 9491825 — intervention group
Group type: COMPARATOR
Intervention: Unilateral forearm plethysmography (FBF) at rest
Number of subjects: 9
Study 9491825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral forearm plethysmography (FBF ratios) after ipsilateral exercise
Number of subjects: 9
Study 9491825 — intervention group
Group type: COMPARATOR
Intervention: Unilateral forearm plethysmography (FBF) after ipsilateral exercise
Number of subjects: 9
Study 9491825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral forearm plethysmography (FBF ratios) 20 min after exercise
Number of subjects: 9
Study 9491825 — intervention group
Group type: COMPARATOR
Intervention: Unilateral forearm plethysmography (FBF) 20 min after exercise
Number of subjects: 9
Study 9491825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral forearm vascular resistance (FVR) ratio
Number of subjects: 9
Study 9491825 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (FBF ratios)
Number of subjects: 9
Study 9491825 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion (FBF)
Number of subjects: 9
Study 9491825 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (FBF ratios)
Number of subjects: 9
Study 9491825 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline infusion (FBF)
Number of subjects: 9
Study 7828793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg b.i.d.)
Number of subjects: 14
Study 7828793 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg b.i.d.)
Number of subjects: 14
Study 7828793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3144615 — intervention group
Group type: COMPARATOR
Intervention: Short-term MF chemotherapy (mitomycin C 0.04 mg/kg plus 5-fluorouracil 5.0 mg/kg x 6 bolus i.v.)
Number of subjects: 0
Study 3144615 — intervention group
Group type: EXPERIMENTAL
Intervention: MF plus long-term HCFU chemotherapy (HCFU 6-12 mg/kg/day over 12 weeks, p.o.)
Number of subjects: 0
Study 30113526 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg daily)
Number of subjects: 30
Study 30113526 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (10 mg daily)
Number of subjects: 30
Study 28463633 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (RIC)
Number of subjects: 129
Study 28463633 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative conditioning (MAC)
Number of subjects: 129
Study 25526832 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Treatment (IT) group
Number of subjects: 24
Study 25526832 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) group
Number of subjects: 24
Study 23385285 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m), Carboplatin (6 times AUC), Vorinostat (200 mg) every 28 days for 6 cycles
Number of subjects: 18
Study 23385285 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m) and Vorinostat (400 mg) maintenance chemotherapy every 28 days for 12 cycles
Number of subjects: 18
Study 23385285 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary induction chemotherapy
Number of subjects: 18
Study 23385285 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe gastrointestinal events
Number of subjects: 18
Study 20951505 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGeted Intraoperative radioTherapy (Targit) boost with a single dose of 20 Gy
Number of subjects: 299
Study 20951505 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGeted Intraoperative radioTherapy (Targit) boost
Number of subjects: 299
Study 18270182 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase support continued for 3 weeks after first ultrasound (Group A)
Number of subjects: 257
Study 18270182 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase support stopped on the day of first ultrasound (Group B)
Number of subjects: 257
Study 17236593 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 0.15 U/kg daily from day 3 to day 9 after operation
Number of subjects: 48
Study 17236593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12895016 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy based on a two‐stage model of trauma treatment including Dialectical Behavior Therapy skills and writing assignments
Number of subjects: 24
Study 12895016 — intervention group
Group type: COMPARATOR
Intervention: No-contact comparison condition
Number of subjects: 24
Study 11198553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 215
Study 11198553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 9751910 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg/kg each of morphine and midazolam
Number of subjects: 80
Study 9751910 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg/kg morphine and 50 microg/kg midazolam
Number of subjects: 80
Study 9751910 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/kg morphine and 75 microg/kg midazolam
Number of subjects: 80
Study 9751910 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/kg each of morphine and midazolam
Number of subjects: 80
Study 8455175 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustments to remove significant slides and nonworking-side interferences
Number of subjects: 51
Study 8455175 — intervention group
Group type: COMPARATOR
Intervention: Mock occlusal adjustment
Number of subjects: 51
Study 3940501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg/d) + Metoclopramide (40 mg/d)
Number of subjects: 25
Study 3940501 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1200 mg/d) + Placebo
Number of subjects: 25
Study 3940501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine + Metoclopramide
Number of subjects: 25
Study 3940501 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine + Placebo
Number of subjects: 25
Study 29512308 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion trial (arterial occlusion applied during recovery)
Number of subjects: 45
Study 29512308 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no arterial occlusion applied during recovery)
Number of subjects: 45
Study 29512308 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion trial
Number of subjects: 45
Study 26984513 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE) program, 0.5-1 hour duration at least twice weekly for at least 3 months, with continuation encouraged thereafter.
Number of subjects: 45
Study 26984513 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE) program
Number of subjects: 45
Study 25516338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-Carboplatin-Bevacizumab (PemCBev)
Number of subjects: 94
Study 25516338 — intervention group
Group type: COMPARATOR
Intervention: Academic vs Community settings
Number of subjects: 94
Study 22951014 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg b.i.d. in combination with two-drug platinum-based chemotherapy
Number of subjects: 316
Study 22951014 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with two-drug platinum-based chemotherapy
Number of subjects: 316
Study 19960257 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with amantadine (200 mg daily)
Number of subjects: 124
Study 19960257 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (peginterferon alpha-2a plus weight-based ribavirin for 48 weeks)
Number of subjects: 124
Study 18256841 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment via intravitreal administration
Number of subjects: 0
Study 18256841 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring with Optical Coherence Tomography (OCT)
Number of subjects: 0
Study 18256841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical follow-up and visual acuity assessment
Number of subjects: 0
Study 16202046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual plate-type RPDs
Number of subjects: 36
Study 16202046 — intervention group
Group type: COMPARATOR
Intervention: Lingual bar-type RPDs
Number of subjects: 36
Study 16202046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RPD types
Number of subjects: 36
Study 12465698 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (DD) of normal-release morphine at bedtime
Number of subjects: 20
Study 12465698 — intervention group
Group type: COMPARATOR
Intervention: Single dose (SD) of normal-release morphine at bedtime
Number of subjects: 20
Study 10709388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac, 60 mg i.v.
Number of subjects: 60
Study 10709388 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol, 2 g i.v.
Number of subjects: 60
Study 10709388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol, 200 mg i.v.
Number of subjects: 60
Study 7491837 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal ERT (50 micrograms 17‐beta‐estradiol/24 hours)
Number of subjects: 42
Study 7491837 — intervention group
Group type: COMPARATOR
Intervention: Oral ERT (0.6 mg conjugated estrogens + 5 mg medrogestone on days 11-21 for three cycles)
Number of subjects: 42
Study 2109336 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analog
Number of subjects: 38
Study 2109336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7379334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 16
Study 7379334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31315240 — intervention group
Group type: EXPERIMENTAL
Intervention: National telephone counselling for smoking cessation
Number of subjects: 469
Study 28031424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalantercept 0.6, 0.9, or 1.2 mg/kg subcutaneously every 3 weeks plus axitinib 5 mg by mouth twice daily
Number of subjects: 29
Study 28031424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalantercept plus axitinib
Number of subjects: 29
Study 26020821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide ophthalmic suspension
Number of subjects: 30
Study 24382318 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational mental health intervention
Number of subjects: 59
Study 24382318 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 59
Study 22180255 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training
Number of subjects: 48
Study 22180255 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 48
Study 19683731 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (1.3, 2.9 or 3.9 mg daily)
Number of subjects: 57
Study 19683731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxybutynin (5, 10 or 15 mg daily)
Number of subjects: 57
Study 19683731 — intervention group
Group type: COMPARATOR
Intervention: Transdermal oxybutynin
Number of subjects: 57
Study 19683731 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 57
Study 17997936 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional needle acupuncture
Number of subjects: 99
Study 17997936 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (without skin penetration)
Number of subjects: 99
Study 11045862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 7.5, 15, 22.5, and 30 mg bid
Number of subjects: 136
Study 11045862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 8960715 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (800 mg, t.i.d.)
Number of subjects: 152
Study 8960715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 1552095 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (1,500 mg/day for days 1-3, then 1,500 mg + verapamil 240 mg/day for days 4-6)
Number of subjects: 40
Study 1552095 — intervention group
Group type: COMPARATOR
Intervention: Quinidine and Verapamil (1,500 mg + 240 mg/day)
Number of subjects: 40
Study 1552095 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (1,200 mg/day intravenously for days 1-3, then 800 mg/day orally for days 4-14)
Number of subjects: 40
Study 3888731 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily treatment with 1% tioconazole cream
Number of subjects: 205
Study 3888731 — intervention group
Group type: COMPARATOR
Intervention: Twice daily treatment with 1% tioconazole cream
Number of subjects: 205
Study 31306390 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Bacillus coagulans (iBC)
Number of subjects: 16
Study 31306390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study 29746891 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (500 mg/day)
Number of subjects: 20
Study 29746891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26702991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg, Bicalutamide 50 mg daily, and Tamoxifen 10 mg daily for 3 months (D + B group)
Number of subjects: 60
Study 26702991 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonists and Bicalutamide daily for 1 month (LHRH group)
Number of subjects: 60
Study 26702991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride and Bicalutamide (D + B group)
Number of subjects: 60
Study 26702991 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonists
Number of subjects: 60
Study 23895176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 : 80 000 epinephrine concentration in 2% lidocaine
Number of subjects: 62
Study 23895176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 : 200 000 epinephrine concentration in 2% lidocaine
Number of subjects: 62
Study 23116437 — intervention group
Group type: COMPARATOR
Intervention: Cemented THR
Number of subjects: 51
Study 23116437 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Hybrid THR
Number of subjects: 51
Study 20386431 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted dalteparin (WAD)
Number of subjects: 39
Study 20386431 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 39
Study 18777847 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16401307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/day)
Number of subjects: 15
Study 16401307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12634965 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-interleukin-2 scintigraphy
Number of subjects: 29
Study 12634965 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO labelled granulocytes scintigraphy
Number of subjects: 29
Study 12634965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 99mTc-interleukin-2 and 99mTc-HMPAO scintigraphy
Number of subjects: 29
Study 12634965 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO scintigraphy
Number of subjects: 29
Study 10666820 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym
Number of subjects: 0
Study 10666820 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 0
Study 10666820 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymes
Number of subjects: 0
Study 10666820 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study 8918967 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation protocol including aerobic arm training sessions (Group A)
Number of subjects: 8
Study 8918967 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program (Group B)
Number of subjects: 8
Study 1888238 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil capsules (4.5 g of omega-3 fatty acids, or nine to 18 capsules daily)
Number of subjects: 0
Study 1888238 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil capsules
Number of subjects: 0
Study 31892609 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3/day
Number of subjects: 0
Study 31892609 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3/day
Number of subjects: 0
Study 31892609 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU vitamin D3/day
Number of subjects: 0
Study 31892609 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of vitamin D3
Number of subjects: 0
Study 29462639 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received explicit instruction to avoid any unwanted finger movements)
Number of subjects: 0
Study 29462639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no explicit instruction to avoid unwanted finger movements)
Number of subjects: 0
Study 27488390 — intervention group
Group type: EXPERIMENTAL
Intervention: The GOOD life intervention (social norms components including face-to-face communication, print communication, and interactive media)
Number of subjects: 1400
Study 27488390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1400
Study 25376940 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐guided fluid management
Number of subjects: 138
Study 25376940 — intervention group
Group type: COMPARATOR
Intervention: Fluid management based only on clinical information
Number of subjects: 138
Study 22989293 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of atherosclerotic renal artery stenosis (ARAS) >50%
Number of subjects: 37
Study 22989293 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of ARAS
Number of subjects: 37
Study 22989293 — intervention group
Group type: COMPARATOR
Intervention: Presence of ARAS
Number of subjects: 37
Study 22989293 — intervention group
Group type: COMPARATOR
Intervention: Presence and extent of late gadolinium enhancement (myocardial fibrosis)
Number of subjects: 37
Study 22989293 — intervention group
Group type: COMPARATOR
Intervention: End diastolic volume
Number of subjects: 37
Study 22989293 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular mass index
Number of subjects: 37
Study 22989293 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 37
Study 22989293 — intervention group
Group type: COMPARATOR
Intervention: Presence of ischemic pattern of late enhancement
Number of subjects: 37
Study 20534140 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physiotherapy
Number of subjects: 90
Study 20534140 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise protocol
Number of subjects: 90
Study 17714851 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-based course (3-hour training)
Number of subjects: 30
Study 17714851 — intervention group
Group type: COMPARATOR
Intervention: Self-training using a poster, manikin, and training AED
Number of subjects: 30
Study 15598949 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP-ABVD
Number of subjects: 75
Study 15598949 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 75
Study 12860772 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d aripiprazole
Number of subjects: 404
Study 12860772 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d aripiprazole
Number of subjects: 404
Study 12860772 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/d risperidone
Number of subjects: 404
Study 12860772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 12860772 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d aripiprazole and 6 mg/d risperidone
Number of subjects: 404
Study 10788759 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 10788759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0